Stephan Glund

Idarucizumab for Dabigatran Reversal

Charles V. Pollack, Paul A. Reilly, John W. Eikelboom et al. · New England Journal of Medicine · 2015 · 1.4K citations

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Charles V. Pollack, Paul Reilly, Joanne van Ryn et al. · New England Journal of Medicine · 2017 · 1.1K citations · Full text

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

Stephan Glund, Joachim Stangier, Michael Schmohl et al. · The Lancet · 2015 · 317 citations

Thrombosis, Venous Thrombosis, Cardiovascular Disease +8

AMPK-Mediated AS160 Phosphorylation in Skeletal Muscle Is Dependent on AMPK Catalytic and Regulatory Subunits

Jonas T. Treebak, Stephan Glund, Atul S. Deshmukh et al. · Diabetes · 2006 · 277 citations · Full text

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

Viktoria Moschetti, Stephen H. Norris, Joachim Stangier et al. · Thrombosis and Haemostasis · 2015 · 244 citations

Drug Safety, Translational Medicine, Monoclonal Antibody Fragment +15